AU2015330824A1 - MRI imaging of amyloid plaque using liposomes - Google Patents

MRI imaging of amyloid plaque using liposomes Download PDF

Info

Publication number
AU2015330824A1
AU2015330824A1 AU2015330824A AU2015330824A AU2015330824A1 AU 2015330824 A1 AU2015330824 A1 AU 2015330824A1 AU 2015330824 A AU2015330824 A AU 2015330824A AU 2015330824 A AU2015330824 A AU 2015330824A AU 2015330824 A1 AU2015330824 A1 AU 2015330824A1
Authority
AU
Australia
Prior art keywords
phospholipid
liposomal composition
polymer
aromatic
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015330824A
Other languages
English (en)
Inventor
Ananth Annapragada
Mayank Srivastava
Eric A. Tanifum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas Childrens Hospital
Original Assignee
Texas Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Childrens Hospital filed Critical Texas Childrens Hospital
Publication of AU2015330824A1 publication Critical patent/AU2015330824A1/en
Assigned to ANNAPRAGADA, ANANTH, SRIVASTAVA, MAYANK, TANIFUM, Eric, Texas Children’s Hospital reassignment ANNAPRAGADA, ANANTH Amend patent request/document other than specification (104) Assignors: ANNAPRAGADA, ANANTH, SRIVASTAVA, MAYANK, TANIFUM, Eric, TEXAS CHILDREN'S HOSPTIAL
Priority to AU2021203388A priority Critical patent/AU2021203388B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015330824A 2014-10-08 2015-10-08 MRI imaging of amyloid plaque using liposomes Abandoned AU2015330824A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021203388A AU2021203388B2 (en) 2014-10-08 2021-05-25 MRI Imaging Of Amyloid Plaque Using Liposomes

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462061514P 2014-10-08 2014-10-08
US62/061,514 2014-10-08
US201562111057P 2015-02-02 2015-02-02
US62/111,057 2015-02-02
PCT/US2015/054732 WO2016057812A1 (en) 2014-10-08 2015-10-08 Mri imaging of amyloid plaque using liposomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021203388A Division AU2021203388B2 (en) 2014-10-08 2021-05-25 MRI Imaging Of Amyloid Plaque Using Liposomes

Publications (1)

Publication Number Publication Date
AU2015330824A1 true AU2015330824A1 (en) 2017-05-25

Family

ID=55653789

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015330824A Abandoned AU2015330824A1 (en) 2014-10-08 2015-10-08 MRI imaging of amyloid plaque using liposomes
AU2021203388A Active AU2021203388B2 (en) 2014-10-08 2021-05-25 MRI Imaging Of Amyloid Plaque Using Liposomes

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021203388A Active AU2021203388B2 (en) 2014-10-08 2021-05-25 MRI Imaging Of Amyloid Plaque Using Liposomes

Country Status (10)

Country Link
US (4) US9744251B2 (enExample)
EP (3) EP3542828A1 (enExample)
JP (1) JP6505235B2 (enExample)
KR (1) KR102409017B1 (enExample)
CN (1) CN107106708B (enExample)
AU (2) AU2015330824A1 (enExample)
CA (1) CA2963941C (enExample)
ES (2) ES3032054T3 (enExample)
MX (1) MX371295B (enExample)
WO (1) WO2016057812A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6212032B2 (ja) 2011-04-06 2017-10-18 ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 脂質ベースのナノ粒子
EP2756459B1 (en) 2012-01-20 2020-12-09 Ananth Annapragada Methods and compositions for objectively characterizing medical images
EP3542828A1 (en) 2014-10-08 2019-09-25 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes
MY196981A (en) 2016-07-22 2023-05-16 Ac Immune Sa Compounds for imaging tau protein aggregates
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
EP3512570B1 (en) * 2016-09-16 2024-08-28 Texas Children's Hospital Liposomal gadolinium (gd) contrast agent for t1-mri
CN110022859B (zh) 2016-11-30 2022-10-28 德克萨斯州儿童医院 具有独特的mr特征用于脂质体19f mri探针的亲水性氟化分子
WO2019145292A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
US20210008204A1 (en) * 2018-03-29 2021-01-14 Microvascular Therapeutics LLC Compositions and methods of detecting and treating alzheimer's disease
US20210252175A1 (en) 2018-06-08 2021-08-19 Ac Immune Sa Novel compounds for diagnosis
EP3914230A4 (en) * 2019-01-24 2023-06-07 Alzeca Biosciences, Llc <SMALLCAPS/>? ? ?FUNCTIONALIZED LIPOSOMES FOR IMAGE MISFOLDED PROTEINS
JP7702381B2 (ja) * 2019-07-08 2025-07-03 アルゼカ バイオサイエンシズ、エルエルシー タウ病理のためのターゲティングリガンド
US11614451B2 (en) 2019-07-08 2023-03-28 Alzeca Biosciences, LLC Targeting ligands for tau pathology
CN115916263B (zh) * 2020-01-29 2025-10-03 德克萨斯儿童医院 用于淀粉样蛋白沉积mri的靶向对比剂
US20210252170A1 (en) * 2020-02-12 2021-08-19 Texas Children's Hospital Targeted contrast agents for mri of alpha-synuclein deposition
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
CN115970009A (zh) * 2023-02-08 2023-04-18 丽水市中心医院 Vhpk多肽修饰的荧光纳米脂质体给药系统、其制备方法及应用
CN116869938A (zh) * 2023-07-26 2023-10-13 安徽医科大学 一种1,2,4-噁二唑-吡啶脂质体及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
EP0752889B1 (en) 1994-03-28 2002-06-26 Nycomed Imaging AS Liposomes containing a x-ray- or ultrasound contrast agent
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
EP1233752B1 (en) 1999-11-30 2005-01-26 The Arizona Board of Regents on behalf of The University of Arizona Radiation sensitive liposomes
US7029655B2 (en) 2000-10-04 2006-04-18 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002094191A2 (en) 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US7138136B2 (en) 2002-03-05 2006-11-21 Cleveland State University Agglomerated particles for aerosol drug delivery
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
WO2006032705A2 (en) 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
US20090170957A1 (en) 2005-10-13 2009-07-02 Antonio Cruz Scyllo-inositol derivatives and their use in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
WO2007048019A2 (en) 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
US7858803B2 (en) 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
US20110311457A1 (en) 2007-07-26 2011-12-22 Nanoscan Imaging, Llc Methods for imaging vascular inflammation using improved nanoparticle contrast agents
EP2217146A4 (en) 2007-12-05 2015-10-14 Marval Biosciences Inc NANOMETRIC SCALE CONTRAST AGENTS AND METHODS OF USE
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
ITMI20081052A1 (it) 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
US20090311191A1 (en) 2008-06-13 2009-12-17 Ananth Annapragada Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US20120003159A1 (en) 2009-03-19 2012-01-05 Board Of Regents Of The University Of Texas System Compositions and methods for enhancing contrast in imaging
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
WO2012119117A1 (en) 2011-03-02 2012-09-07 Sensulin, Llc Vesicle compositions
JP6212032B2 (ja) * 2011-04-06 2017-10-18 ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 脂質ベースのナノ粒子
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
EP2756459B1 (en) 2012-01-20 2020-12-09 Ananth Annapragada Methods and compositions for objectively characterizing medical images
US9377472B2 (en) * 2012-04-30 2016-06-28 Amoneta Diagnostics Biological complex specific for Alzheimer's disease detection in vitro and use thereof
KR20150127245A (ko) 2013-03-14 2015-11-16 켈탁시스, 인코퍼레이티드 류코트라이엔 a4 가수분해효소의 저해제
EP3542828A1 (en) 2014-10-08 2019-09-25 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes

Also Published As

Publication number Publication date
US9744251B2 (en) 2017-08-29
CN107106708A (zh) 2017-08-29
AU2021203388A1 (en) 2021-06-24
EP4035688A1 (en) 2022-08-03
US11141495B2 (en) 2021-10-12
EP3204051A1 (en) 2017-08-16
US20200069820A1 (en) 2020-03-05
EP4035688B1 (en) 2025-03-26
US10537649B2 (en) 2020-01-21
BR112017007238A2 (pt) 2018-01-16
CN107106708B (zh) 2021-06-18
US20160101197A1 (en) 2016-04-14
JP2017532378A (ja) 2017-11-02
JP6505235B2 (ja) 2019-04-24
EP3542828A1 (en) 2019-09-25
HK1243335A1 (zh) 2018-07-13
US20170080111A1 (en) 2017-03-23
KR20170103748A (ko) 2017-09-13
AU2021203388B2 (en) 2024-05-30
US20200179540A1 (en) 2020-06-11
CA2963941A1 (en) 2016-04-14
MX371295B (es) 2020-01-24
KR102409017B1 (ko) 2022-06-16
EP3204051B1 (en) 2019-05-29
EP4035688C0 (en) 2025-03-26
ES3032054T3 (en) 2025-07-15
WO2016057812A1 (en) 2016-04-14
EP3204051A4 (en) 2018-06-27
CA2963941C (en) 2023-08-01
MX2017004695A (es) 2018-01-24
ES2743704T3 (es) 2020-02-20

Similar Documents

Publication Publication Date Title
AU2021203388B2 (en) MRI Imaging Of Amyloid Plaque Using Liposomes
Tanifum et al. A novel liposomal nanoparticle for the imaging of amyloid plaque by magnetic resonance imaging
KR102035187B1 (ko) 지질-기반 나노입자들
EP2065058A1 (en) Non-spherical contrast agents for CEST MRI based on bulk magnetic susceptibility effect
Lacerda et al. Metal complexes for multimodal imaging of misfolded protein-related diseases
JP7545393B2 (ja) 誤って折りたたまれたタンパク質を画像化するための機能化リポソーム
HK40010427A (en) Mri imaging of amyloid plaque using liposomes
BR112017007238B1 (pt) Composição lipossomal compreendendo um conjugado fosfolipídiopolímero-aromático e um agente potencializador de contraste de imagem de ressonância magnética não radioativo para geração de imagem de depósitos amiloides
US20230136718A1 (en) Functionalized liposomes for imaging misfolded proteins
HK1243335B (zh) 使用脂质体进行的淀粉样蛋白斑mri成像
Aime et al. Recent Developments of Contrast Agents, CEST and Low Fields

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SRIVASTAVA, M.

Free format text: FORMER NAME(S): TEXAS CHILDREN'S HOSPTIAL ; ANNAPRAGADA, ANANTH; TANIFUM, ERIC; SRIVASTAVA, MAYANK

Owner name: ANNAPRAGADA, A.

Free format text: FORMER NAME(S): TEXAS CHILDREN'S HOSPTIAL ; ANNAPRAGADA, ANANTH; TANIFUM, ERIC; SRIVASTAVA, MAYANK

Owner name: TEXAS CHILDREN'S HOSPITAL

Free format text: FORMER NAME(S): TEXAS CHILDREN'S HOSPTIAL ; ANNAPRAGADA, ANANTH; TANIFUM, ERIC; SRIVASTAVA, MAYANK

Owner name: TANIFUM, E.

Free format text: FORMER NAME(S): TEXAS CHILDREN'S HOSPTIAL ; ANNAPRAGADA, ANANTH; TANIFUM, ERIC; SRIVASTAVA, MAYANK

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted